Kinases are cellular control switches. When they malfunction, they can cause cancer. The coronavirus hijacks these kinases to replicate, and cancer drugs that target them could fight COVID-19.
Academic rigour, journalistic flair
Articles on Drugs
Displaying 141 - 160 of 455 articles
After firms add more women to their board, dangerous medical products are recalled more quickly.
Scanning through billions of chemicals to find a few potential drugs for treating COVID-19 requires computers that harness together thousands of processors.
New rules attempt to curb opioid-related deaths in Australia. These changes are a step in the right direction – but we need to tread carefully to avoid unintended consequences.
The Covid-19 pandemic has laid bare Europe’s vulnerability to drug-supply disruption. Still, it remains by far the world leader in pharmaceutical products.
People who used strains with higher levels of THC were two times more likely to have anxiety – and four times more likely to report problems from their use.
Production of coca leaf, the raw material in cocaine, is surging in Peru despite 40 years of forced eradication designed to convince farmers to abandon it. Bolivia shows a better way forward.
New manufacturing processes will revolutionise the way we take our medicines.
It’s difficult to find toilet paper, but apparently there’s no shortage of cannabis.
Chronic pain is everyone’s problem. It’s costly, debilitating and, according to new statistics, increasingly common. Reversing the trend is achieveable but far from easy.
CC BY-NC-ND7.87 MB (download)
In trying to suppress the cannabis market in 1923, the government accidentally helped to form an impressive illegal cannabis economy.
Researchers at the University of California, San Francisco, identified nine existing drugs that show promise to treat COVID-19. The proteins they target haven’t been tried before.
Coronavirus drug trials are underway – a virologist explains what the treatment options may be.
People who use illicit drugs are at increased risk during the coronavirus pandemic. But minimising that risk will improve their well-being and help avoid additional pressure on the health system.
Researchers, scientific journals and health agencies are doing everything they can to speed up coronavirus research. The combination of pace and panic during this pandemic is causing mistakes.
Nigeria’s reliance on drug importation is worrisome as COVID-19 pandemic rages.
Drug shortages occur regularly in the US, even in the best of times. The pharmaceutical supply chain embodies ‘just in time’ shipping and has little built-in redundancy.
Among the more than 20,000 drugs approved by the FDA, there may be some that can treat COVID-19. A team at the University of California, San Francisco, is identifying possible candidates.
Patients taking antipsychotics aren’t being made aware of the risks or side-effects.
An audio version of an in depth article on the history of Ritalin, and what the future holds for the drug.
Top contributors
-
Honorary Fellow, Department of Health Sciences, University of York
-
Adjunct Professor at the National Drug Research Institute (Melbourne based), Curtin University
-
Senior Lecturer of Addiction, Edith Cowan University
-
Professor in Substance Use, Liverpool John Moores University
-
Joel Lexchin is a Friend of The Conversation.
Professor Emeritus of Health Policy and Management, York University, Canada
-
Vice Chancellor’s Senior Research Fellow, Social Equity Research Centre and Digital Ethnography Research Centre, RMIT University
-
Associate Professor of the School of Pharmacy, University of Sydney
-
Professor in Criminal Justice and Faculty Director of Public Engagement, University of Kent
-
Distinguished Professor of Pharmacy Practice, University of Connecticut
-
University of Sydney
-
Lecturer, RMIT University
-
Senior Lecturer in Chemistry, University of Birmingham
-
PhD Candidate, Royal Holloway University of London
-
Senior Lecturer in Criminology, Deakin University
-
Professor & Specialist in Drug Policy, UNSW Sydney
